

Seasonal Influenza Report

San Mateo County Health System, Public Health Policy and Planning 2016-17 Annual Summary

San Mateo County Severe and Fatal Influenza Case Surveillance

The California Department of Public Health (CDPH) mandates reporting of laboratory-confirmed influenza **deaths** under the age of 65. CDPH also requests that cases of influenza that require **intensive care** be reported as well, in an effort to monitor the circulation of new viruses and characterize populations at risk for complications. Severe cases are defined as having laboratory confirmed influenza with hospitalization requiring intensive care or ending in death.

Within San Mateo County, a total of six adult and no pediatric (ages 17 years and under) confirmed severe influenza cases were reported this season (Table 1). Among the cases there were five males and one female, with ages ranging from 23 to 64. Dates of onset ranged from 10/29/16 to 3/13/17* (Figure 4).

In addition to individual case reporting, 16 institutionalized outbreaks of influenza were reported from long term care and skilled nursing facilities during this influenza season. Dates of onset ranged from December 2016 to March 2017. All 16 outbreaks were Influenza A positive.

Table 1

2016-2017 Season
(10/2/2016 — 5/20/2017)*
6
0
0
0
16

*Based on date reported to Public Health

Source: California Reportable Disease Information Exchange (CalREDIE)

PLEASE REPORT TO COMMUNICABLE DISEASE CONTROL

- Report ALL cases of severe febrile respiratory illness and suspected seasonal influenza which are (1) hospitalized in the ICU or (2) deceased by calling (650) 573-2346 or by submitting a Confidential Morbidity Report (CMR) and faxing it to (650) 573-2919.
- Immediately report any respiratory outbreaks in your facility to Communicable Disease Control by calling (650) 573-2346.

INFLUENZA VACCINE COMPOSITION FOR THE 2017-2018 SEASON

For 2017–18, trivalent influenza vaccines will contain:

- An A/Michigan/45/2015 (H1N1)pdm09-like virus
- An A/Hong Kong/4801/2014 (H3N2)-like virus
- A B/Brisbane/60/2008-like (B/Victoria lineage) virus


Quadrivalent vaccines containing two influenza B viruses include the above three antigens and a B/Phuket/3073/2013-like (B/Yamagata lineage) virus.

AVAILABLE VACCINE PRODUCTS

Various influenza vaccine products are anticipated to be available during the 2017–18 season, with vaccine types listed below:

- Trivalent inactivated influenza vaccine (Standard dose)
- Quadrivalent inactivated influenza vaccine (Standard dose)
- Cell culture-based inactivated quadrivalent influenza vaccine (Standard dose)
- Adjuvanted inactivated trivalent influenza vaccine (Standard dose)
- High dose trivalent inactivated influenza vaccine
- Recombinant trivalent influenza vaccine (Standard dose)
- Live attenuated quadrivalent influenza vaccine (Should not be used this season because of concerns regarding low effectiveness against influenza A (H1N1) in the past 2 seasons).

Table 1 describes each type of influenza vaccine, age indications and thimerosal content here.



^{*}Some onset dates are unavailable. As a proxy, the laboratory collection date or the date the case was received by the health department, whichever is earlier, was used.